Advertisement

Topics

Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk

08:53 EDT 14 Jun 2019 | Medscape

Measurable residual disease, detected with next-generation genomic sequencing, is associated with a significantly increased risk for relapse. Experts question the prognostic ability of other assessment tools.
Medscape Medical News

Original Article: Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk

NEXT ARTICLE

More From BioPortfolio on "Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...